SciELO - Scientific Electronic Library Online

 
vol.15 número2Difficulties with interferon treatment in former intravenous drug usersClinical aspects of influenza A (H1N1) in HIV-infected individuals in São Paulo during the pandemic of 2009 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Brazilian Journal of Infectious Diseases

versión impresa ISSN 1413-8670

Resumen

NOGUEIRA, Keite da Silva et al. Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae. Braz J Infect Dis [online]. 2011, vol.15, n.2, pp. 167-169. ISSN 1413-8670.  http://dx.doi.org/10.1590/S1413-86702011000200014.

The objective of this study was to evaluate the susceptibility to cefepime of a large group of ESBL- producing enterobacteria recently isolated in a Brazilian teaching hospital . The study included 280 strains of ESBL-producing enterobacteria, isolated between 2005 and 2008. The presence of the genes blaCTX-M, blaTEM and blaSHV was determined by PCR and confirmed by nucleotide sequencing. Susceptibility testing for cefepime was performed by disc-diffusion, agar dilution method and E-test®. Among the isolates, 34 (12.1%) presented a cefepime inhibition zone > 21 and MIC < 8 mg/L by agar dilution and E-strip methods. The use of cefepime for the treatment of infections caused by ESBL-producing bacteria has been controversial. Some studies of PD/PK show the probability of achieving the required PD parameters for cefepime, when the MICs were < 8 mg/L, whereas others have reported therapeutic failure with the same MIC. Additional data is essential to come to terms about the report and treatment with cefepime in ESBL-producing organisms especially when these microorganisms are isolated from sterile sites and from critically ill patients.

Palabras llave : enterobacteriaceae; beta-lactamases; cephalosporin resistance.

        · texto en Inglés     · pdf en Inglés